These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24683185)

  • 1. HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.
    Meza-Romero R; Benedek G; Yu X; Mooney JL; Dahan R; Duvshani N; Bucala R; Offner H; Reiter Y; Burrows GG; Vandenbark AA
    J Immunol; 2014 May; 192(9):4164-73. PubMed ID: 24683185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.
    Benedek G; Meza-Romero R; Jordan K; Keenlyside L; Offner H; Vandenbark AA
    J Neuroinflammation; 2015 Jun; 12():123. PubMed ID: 26104759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.
    Meza-Romero R; Benedek G; Gerstner G; Kent G; Nguyen H; Offner H; Vandenbark AA
    Metab Brain Dis; 2019 Feb; 34(1):153-164. PubMed ID: 30353480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.
    Benedek G; Zhu W; Libal N; Casper A; Yu X; Meza-Romero R; Vandenbark AA; Alkayed NJ; Offner H
    Metab Brain Dis; 2014 Mar; 29(1):37-45. PubMed ID: 24122483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Near Cure" treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct.
    Vandenbark AA; Meza-Romero R; Wiedrick J; Gerstner G; Seifert H; Kent G; Piechycna M; Benedek G; Bucala R; Offner H
    Cell Immunol; 2022 Aug; 378():104561. PubMed ID: 35738135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief report: Enhanced DRα1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice.
    Vandenbark AA; Meza-Romero R; Wiedrick J; Gerstner G; Headrick A; Kent G; Seifert H; Benedek G; Bucala R; Offner H
    Cell Immunol; 2021 Dec; 370():104439. PubMed ID: 34607646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.
    Benedek G; Meza-Romero R; Andrew S; Leng L; Burrows GG; Bourdette D; Offner H; Bucala R; Vandenbark AA
    Eur J Immunol; 2013 May; 43(5):1309-21. PubMed ID: 23576302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.
    Vandenbark AA; Meza-Romero R; Benedek G; Andrew S; Huan J; Chou YK; Buenafe AC; Dahan R; Reiter Y; Mooney JL; Offner H; Burrows GG
    J Autoimmun; 2013 Feb; 40():96-110. PubMed ID: 23026773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.
    Yang L; Liu Z; Ren H; Zhang L; Gao S; Ren L; Chai Z; Meza-Romero R; Benedek G; Vandenbark AA; Offner H; Li M
    Metab Brain Dis; 2017 Oct; 32(5):1395-1402. PubMed ID: 28303450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
    Meza-Romero R; Benedek G; Leng L; Bucala R; Vandenbark AA
    Metab Brain Dis; 2016 Apr; 31(2):249-55. PubMed ID: 26851955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.
    Klasen C; Ziehm T; Huber M; Asare Y; Kapurniotu A; Shachar I; Bernhagen J; El Bounkari O
    Cell Signal; 2018 Jun; 46():32-42. PubMed ID: 29476963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of MIF and CD74 in leukemic cell lines: correlation to DR expression destiny.
    Georgouli M; Papadimitriou L; Glymenaki M; Patsaki V; Athanassakis I
    Biol Chem; 2016 Jun; 397(6):519-28. PubMed ID: 26866879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase.
    Fan H; Hall P; Santos LL; Gregory JL; Fingerle-Rowson G; Bucala R; Morand EF; Hickey MJ
    J Immunol; 2011 Apr; 186(8):4915-24. PubMed ID: 21411731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.
    Wang J; Ye Q; Xu J; Benedek G; Zhang H; Yang Y; Liu H; Meza-Romero R; Vandenbark AA; Offner H; Gao Y
    Transl Stroke Res; 2017 Jun; 8(3):284-293. PubMed ID: 27988839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.
    Zheng YX; Yang M; Rong TT; Yuan XL; Ma YH; Wang ZH; Shen LS; Cui L
    World J Gastroenterol; 2012 May; 18(18):2253-61. PubMed ID: 22611320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIF signal transduction initiated by binding to CD74.
    Leng L; Metz CN; Fang Y; Xu J; Donnelly S; Baugh J; Delohery T; Chen Y; Mitchell RA; Bucala R
    J Exp Med; 2003 Jun; 197(11):1467-76. PubMed ID: 12782713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74.
    Meza-Romero R; Benedek G; Jordan K; Leng L; Pantouris G; Lolis E; Bucala R; Vandenbark AA
    Cytokine; 2016 Dec; 88():62-70. PubMed ID: 27573366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
    Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
    Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair.
    Marsh LM; Cakarova L; Kwapiszewska G; von Wulffen W; Herold S; Seeger W; Lohmeyer J
    Am J Physiol Lung Cell Mol Physiol; 2009 Mar; 296(3):L442-52. PubMed ID: 19136583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD74 is a functional MIF receptor on activated CD4
    Zhang L; Woltering I; Holzner M; Brandhofer M; Schaefer CC; Bushati G; Ebert S; Yang B; Muenchhoff M; Hellmuth JC; Scherer C; Wichmann C; Effinger D; Hübner M; El Bounkari O; Scheiermann P; Bernhagen J; Hoffmann A
    Cell Mol Life Sci; 2024 Jul; 81(1):296. PubMed ID: 38992165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.